B
Black Diamond Therapeutics, Inc. (BDTX)
NMS – Real Time Price. Currency in USD
2.83
-0.11 (-3.74%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.83
-0.11 (-3.74%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.46 | 6.05 | 10 | |
| Quick ratio | 8.46 | 5.63 | 10 | |
| Debt to Equity | 0.17 | 0.30 | 9.0 | |
| Debt to Assets | 0.13 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | 70M | N/A |
| Gross Profit | -3M | -437K | -343K | 70M | -265K |
| Operating Income | -93M | -86M | -76M | 20M | -46M |
| Net Income | -91M | -82M | -70M | 22M | -43M |
| EBITDA | -90M | -86M | -75M | 20M | -46M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 0 | 1.0 |
| Next quarter | N/A | 38.52 | 5.5 |
| Current year | -89.8 | -264.1 | 1.0 |
| Next year | -100 | -49.8 | 1.0 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 40.22 | 40.74 | -50.75 | 7.8 |
| Y/Y | -99.99 | -115.97 | -116.32 | -119.15 | 1.0 |
| 3y average | 999 | 52.38 | 62.85 | 58.64 | 10 |
| 5y average | 999 | 19.56 | 29.34 | 19.26 | 9.5 |
| Weighted average score | 7.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $30.1M significantly exceed its total debt $17.9M, ensuring strong financial flexibility
Total current assets $123.0M exceed Total current liabilities $14.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$10.2M limits the company's ability to reinvest or pay down debt